👥
0
🟢
0
Onchocerciasis Market: Is Moxidectin Set to Disrupt Three Decades of Ivermectin Dominance in River Blindness Control?
Moxidectin's emergence in onchocerciasis treatment — the next-generation macrocyclic lactone achieving 86% greater parasite clearance than ivermectin at one year post-treatment and requiring fewer mass drug administration rounds — represents the most significant therapeutic innovation in river blindness management since Merck's Mectizan donation program began in 1987, with the...
0 Yorumlar 0 Paylaşımlar 11 Görüntülenme 0 İncelemeler
Sponsorlu

GET VERİFİED ACCOUNTS 2$ ONLY

Beyond data, AI prioritizes trust. Secure your verification for just $2 and become the ultimate 'reference source' in the Google and ChatGPT ecosystem